WEHI-3 Syngeneic Model Service for Leukemia

The WEHI-3 syngeneic model of leukemia propagates a mineral oil–induced murine myelomonocytic leukemia in fully immunocompetent BALB/c hosts, pairing a five-decade publication pedigree with dissemination formats that read out as organomegaly, survival and innate immune activity. Alfa Cytology delivers the complete WEHI-3 workflow—authenticated cell banking, intraperitoneal, intravenous or subcutaneous inoculation, balanced assignment, scheduled dosing and organ- and survival-based endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of WEHI-3 Syngeneic Model for Leukemia

Few cell lines carry as much history per passage as WEHI-3. In 1969, Warner, Moore and Metcalf at the Walter and Eliza Hall Institute reported a transplantable myelomonocytic leukemia that had arisen in a BALB/c mouse undergoing mineral oil injections—the regimen meant to provoke plasmacytomas instead produced a tumor of mixed monocytic and granulocytic cells with a chloroma’s greenish cast. Transplantation resolved the tumor into four sublines, two retaining the chloroma phenotype (one diploid, one tetraploid) and two non-chloroma variants (one with a hypodiploid 39-chromosome stemline), and muramidase poured out of affected animals at concentrations frequently exceeding 200 µg/mL in serum and urine. The line’s second act was molecular: WEHI-3 turned out to produce interleukin-3 constitutively through activation of the IL-3 gene by a retroviral-like intracisternal A-particle insertion, making it the founding source of murine IL-3—its conditioned medium still feeds IL-3-dependent lines such as 32D and BaF3—and its cells served as the canonical target in the 1982 bioassay that led to tumor necrosis factor’s purification. MHC-restricted antigen presentation by WEHI-3 was demonstrated as early as 1981, and the derivative WEHI-3B remains a reference for G-CSF-induced myeloid differentiation.

Fig 1. Time-course organ burden in the WEHI-3B syngeneic model — macroscopic spleen and liver images at day 31 across five groups, spleen weight rising from ~0.08 g to ~0.45 g (group 3) and liver weight changes, quantifying disease progression from day 5 to day 31 after WEHI-3B inoculation. (Nagarajan, Senthil, et al., 2021)

As an in vivo model, WEHI-3 is refreshingly direct: introduced into BALB/c mice by the intraperitoneal or intravenous route, the cells establish a disseminated leukemia marked by progressive splenomegaly and hepatomegaly, and the efficacy readouts are the classic ones—body, spleen and liver weights, survival, histopathology of spleen, liver and bone marrow, peripheral-blood blast burden and natural-killer-cell activity, the last of which proved decisive in the thymoquinone studies that documented reduced organ weights alongside boosted NK function. A subcutaneous solid-tumor format exists for sponsors wanting caliper-based dosing windows. The cells themselves are macrophage-like, grow semi-adherent with a doubling time of roughly 18–23 hours, express Fc and complement receptors, lysozyme and G-CSF activity, and carry a validated mouse STR profile plus SNP-array strain verification. Caveats deserve respect: a 1969-era line brings subline divergence (WEHI-3 versus WEHI-3B differ), its autocrine IL-3 can confound cytokine-addition experiments, semi-adherent harvesting demands consistency, and the model is BALB/c-bound. Within those boundaries, it remains an economical, immunocompetent mainstay for preclinical leukemia research.

Cell Line Information: WEHI-3

Key characteristics of WEHI-3 and its documented derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, flow cytometry and innate-immunity assay capabilities in-house, Alfa Cytology molds every WEHI-3 engagement around the sponsor’s question—selecting the intraperitoneal, intravenous or subcutaneous format, calibrating inoculum and schedule, and pairing dosing with organ-weight, survival and immune readouts for clean, decision-grade preclinical data.

Workflow of WEHI-3 Syngeneic Model Construction

Construction of the WEHI-3 syngeneic model is an inoculation workflow whose quality rests on verified cells, vigorous BALB/c recipients, route-matched technique and disciplined clinical monitoring. A standard engagement proceeds as follows:

1. Source and qualify cells: WEHI-3 stocks are cleared by mycoplasma PCR and authenticated against the published mouse STR profile; constitutive IL-3 production is documented as a functional identity check, and luciferase labeling is titrated in vitro where imaging readouts are required.
2. Prepare recipients: BALB/c mice (typically 6–8 weeks old) complete acclimation and health screening and are individually marked before inoculation.
3. Prepare the inoculum: log-phase cells are harvested with consistent semi-adherent technique, washed (three washes where cytokine-free designs require removal of autocrine IL-3), counted and checked for viability before resuspension in PBS.
4. Inoculate: cells are delivered intraperitoneally or intravenously (tail vein) for disseminated leukemia, or subcutaneously into the flank where a caliper-tracked solid format is preferred, using consistent technique for each route.
5. Assign groups: leukemia-format animals are randomized by body weight at inoculation; flank-format animals are grouped when tumors become palpable, balanced by tumor volume and body weight.
6. Dose and follow: test articles are administered on schedule; body weight and clinical status are recorded two to three times weekly (daily near endpoints), with survival as the primary leukemia readout and caliper measurements for flank tumors; peripheral-blood smears or CBC can be added on a defined schedule.
7. Terminate and analyze: spleen, liver and body weights are recorded; spleen, liver and bone marrow undergo histopathology; peripheral blood is scored for blast burden; splenic and circulating populations are profiled by flow cytometry (CD11b/Gr-1 lineage, NK markers); NK-cell activity assays and cytokine panels complete the package.

Fig 2. WEHI-3 Syngeneic Model construction workflow.

Case Study-WEHI-3 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the WEHI-3 platform: establishment-phase optimization of inoculum and route, in vivo leukemia progression monitoring with survival and organomegaly readouts, anti-leukemic and differentiation-therapy intervention studies, and systematic endpoint analyses covering histopathology, flow-cytometric lineage profiling and NK-activity assays. Representative survival curves, organ-weight datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

A fifty-year-old line with semi-adherent habits rewards operational care, and that is exactly where Alfa Cytology invests:

• Route-flexible execution spanning intraperitoneal, intravenous and subcutaneous formats.
• Authenticated WEHI-3 banks with STR verification and documented IL-3 production baselines.
• Familiarity with subline nuances (WEHI-3 versus WEHI-3B) and controlled low-passage handling.
• Dissemination-format expertise: organomegaly, survival and blast-burden readouts done by the book.
• In-house NK-activity and flow-cytometric assays matched to the model’s innate-immunity biology.
• Three-wash inoculum preparation for cytokine-controlled designs.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the WEHI-3 syngeneic leukemia model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.